Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Hua Medicine (HUMDF) Stock Price & Analysis

HUMDF Stock Chart & Stats

$0.28-$0.00(-0.36%)
At close: 4:00 PM EDT
$0.3$0.32$0.3427 Jul20 Aug24 Aug2 Sep16 Sep6 Oct
Day’s Range
$0.27 - $0.28
52-Week Range
$0.25 - $0.62
Previous Close
$0.28
Volume
N/A
Average Volume (3M)
33
Market Cap
$269.23M
Enterprise Value
$1.29B
Total Cash (Recent Filing)
$1.07B
Total Debt (Recent Filing)
$354.20M
Price to Earnings (P/E)
―
Beta
0.11
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Rapid 2025 revenue expansion indicates stronger commercial traction for dorzagliatin and growing demand in the company’s diabetes franchise. If maintained, this top-line momentum can broaden market penetration, improve operating leverage, and support greater reinvestment in the product pipeline.

Improved Gross Margin

The substantial gross-margin improvement points to better product economics and more value retained from each sale. Sustained margin expansion would strengthen the economics of commercialization, create greater capacity to absorb research and selling costs, and improve the path toward eventual profitability.

Manageable Leverage

Manageable leverage and restored positive equity provide a more stable financial base for continuing commercialization and development activities. Broadly stable total debt also limits balance-sheet deterioration, preserving flexibility compared with the negative-equity position reported in 2024.

Bears Say

Negative Cash Generation

Negative operating and free cash flow show that reported business performance is not currently translating into internally generated funding. Persistent cash burn could require greater use of financial resources or external funding, reducing flexibility to expand commercialization and advance pipeline programs.

Ongoing Operating Losses

Despite strong revenue growth and better gross margin, the core business remains materially loss-making at the operating and EBITDA levels. This indicates that selling, development, and other operating expenses still outweigh gross profit, leaving the company without sustainable operating profitability.

Volatile Earnings Quality

The sharp disconnect between strongly positive net income and continuing operating losses makes reported earnings less predictable and less representative of recurring business performance. This weakens confidence in profit durability and complicates assessment of when the underlying franchise can become sustainably profitable.

Hua Medicine News

HUMDF FAQ

What was Hua Medicine’s price range in the past 12 months?
Hua Medicine lowest stock price was $0.25 and its highest was $0.62 in the past 12 months.
What is Hua Medicine’s market cap?
Hua Medicine’s market cap is $269.23M.
When is Hua Medicine’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hua Medicine’s earnings last quarter?
Hua Medicine released its earnings results on Aug 20, 2026. The company reported -$0.004 earnings per share for the quarter.
Is Hua Medicine overvalued?
According to Wall Street analysts Hua Medicine’s price is currently Undervalued.
Does Hua Medicine pay dividends?
Hua Medicine does not currently pay dividends.
What is Hua Medicine’s EPS estimate?
Hua Medicine’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine have?
Hua Medicine has 1,056,605,000 shares outstanding.
What happened to Hua Medicine’s price movement after its last earnings report?
Hua Medicine reported an EPS of -$0.004 in its last earnings report. Following the earnings report the stock price went down -1.274%.
Which hedge fund is a major shareholder of Hua Medicine?
Currently, no hedge funds are holding shares in HUMDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology